Adversity Considerations for Thyroid Follicular Cell Hypertrophy and Hyperplasia in Nonclinical Toxicity Studies: Results From the 6th ESTP International Expert Workshop. (December 2020)

• Record Type: Journal Article
• Authors: Huisinga, Maike; Bertrand, Lise; Chamanza, Ronnie; Damiani, Isabelle; Engelhardt, Jeff; Francke, Sabine; Freyberger, Alexius; Harada, Takanori; Harleman, Johannes; Kaufmann, Wolfgang; Keane, Kevin; Köhrle, Josef; Lenz, Barbara; Marty, M. Sue; Melching-Kollmuss, Stephanie; Palazzi, Xavier; Pohlmeyer-Esch, Gabriele; Popp, Andreas; Rosol, Thomas J.; Strauss, Volker; Van den Brink-Knol, Hetty; Wood, Charles E.; Yoshida, Midori
• Is Part Of: Toxicologic pathology. Volume 48:Number 8(2020)
• Page Start: 920
• Page End: 938
• Publication Date: 2020-12
• Subjects: adversity -- thyroid gland -- hypertrophy -- hyperplasia -- hazard -- risk assessment; Pathology -- Periodicals; Toxicology -- Periodicals; Pathology; Toxicology; 615.9
• DOI: 10.1177/0192623320972009
• Languages: English
• ISSNs: 0192-6233

Abstract

The European Society of Toxicologic Pathology organized an expert workshop in May 2018 to address adversity considerations related to thyroid follicular cell hypertrophy and/or hyperplasia (FCHH), which is a common finding in nonclinical toxicity studies that can have important implications for risk assessment of pharmaceuticals, food additives, and environmental chemicals. The broad goal of the workshop was to facilitate better alignment in toxicologic pathology and regulatory sciences on how to determine adversity of FCHH. Key objectives were to describe common mechanisms leading to thyroid FCHH and potential functional consequences; provide working criteria to assess adversity of FCHH in context of associated findings; and describe additional methods and experimental data that may influence adversity determinations. The workshop panel was comprised of representatives from the European Union, Japan, and the United States. Participants shared case examples illustrating issues related to adversity assessments of thyroid changes. Provided here are summary discussions, key case presentations, and panel recommendations. This information should increase consistency in the interpretation of adverse changes in the thyroid based on pathology findings in nonclinical toxicity studies, help integrate new types of biomarker data into the review process, and facilitate a more systematic approach to communicating adversity determinations in toxicology reports.